CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN-γResponses
出版年份 2013 全文链接
标题
CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN-γResponses
作者
关键词
-
出版物
Biomed Research International
Volume 2013, Issue -, Pages 1-11
出版商
Hindawi Limited
发表日期
2013-03-24
DOI
10.1155/2013/636847
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II
- (2014) M. Schnurr et al. JOURNAL OF IMMUNOLOGY
- CpG DNA as a vaccine adjuvant
- (2011) Christian Bode et al. Expert Review of Vaccines
- ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway
- (2011) Nicholas S Wilson et al. IMMUNOLOGY AND CELL BIOLOGY
- Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus
- (2011) V. Dasari et al. JOURNAL OF GENERAL VIROLOGY
- ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells
- (2011) P. Duewell et al. JOURNAL OF IMMUNOLOGY
- Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers
- (2011) Dianna Rynkiewicz et al. VACCINE
- Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV‐Infected Adults with a Toll‐Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial
- (2010) Ole S. Søgaard et al. CLINICAL INFECTIOUS DISEASES
- Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers
- (2010) Debbie Drane et al. Human vaccines & immunotherapeutics
- An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma
- (2010) Collin Jacobs et al. INTERNATIONAL JOURNAL OF CANCER
- Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
- (2009) T. Nicholaou et al. CLINICAL CANCER RESEARCH
- Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant
- (2009) Eugene Maraskovsky et al. IMMUNOLOGY AND CELL BIOLOGY
- A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals
- (2009) Ruth D. Ellis et al. VACCINE
- A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults
- (2009) Issaka Sagara et al. VACCINE
- CPG 7909 Adjuvant plus Hepatitis B Virus Vaccination in HIV‐Infected Adults Achieves Long‐Term Seroprotection for Up to 5 Years
- (2008) C. L. Cooper et al. CLINICAL INFECTIOUS DISEASES
- Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
- (2008) Gregory E. D. Mullen et al. PLoS One
- Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS)
- (2007) J.E. Eyles et al. MICROBIAL PATHOGENESIS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More